Background

This study assumes that hematopoietic stem cell transplantation (HSCT) is the only curative therapy for hematologic malignancies such as acute leukemia and myelodysplastic syndromes (MDS). Post‑transplant reconstitution of patient T cells and NK cells directly influences the risk of relapse and infection. Prior research has largely focused on cell counts, but functional data assessing actual immune defense capacity have been limited. Consequently, a novel approach to quantifying immune function was needed.

Methods and Measurements

The research team stimulated patient blood samples with non‑specific agonists (anti‑CD3, anti‑TLR7) and measured the resulting cytokine profile. Targets included the activity of various T‑cell subsets (Th1, Th2, Th17, regulatory T cells) and NK cells. Cytokines are signaling molecules released upon immune cell activation, and their concentrations serve as proxies for cellular function. This dataset provides functional information that is distinct from conventional surface‑phenotype analyses.

Clinical Significance

By linking immune‑function data with rates of relapse, infection, and graft‑versus‑host disease (GVHD), the study provides a basis for tailoring immunosuppressive regimens and optimizing the timing of donor lymphocyte infusion (DLI). When functional decline is detected, infection‑prophylaxis strategies can be intensified or GVHD risk reassessed. This approach may improve patient survival and reduce treatment costs.

Future Applicability

These findings have the potential to be expanded as a standardized immune‑function monitoring protocol across other transplant centers. They also provide clinical validation for companies developing cellular immunotherapies or biomarker‑based diagnostic kits. In the long term, function‑driven immune management could become the standard of care paradigm following HSCT.